Wegovy 7.2mg Dose Guide: What to Know

In January 2026, the MHRA approved a new 7.2mg maintenance dose of Wegovy (semaglutide) for weight management in the UK. This is a significant step up from the previous maximum of 2.4mg per week. Here is what the new dose means, who it is for, and how to access it.

What Changed: 2.4mg to 7.2mg

The original Wegovy dosing topped out at 2.4mg per week. The new 7.2mg dose is three times higher. This is not a separate drug. It is the same semaglutide molecule at a higher concentration, delivered via a reformulated injection pen.

Key facts:

• Same active ingredient as Wegovy 2.4mg and Ozempic
• Approved by the MHRA in January 2026
• Intended for patients who have plateaued on 2.4mg or need greater weight reduction
• Once-weekly subcutaneous injection (same injection site rotation)
• Available via private clinics now; NHS rollout expected mid-to-late 2026

Why a Higher Dose?

The clinical rationale is straightforward. Some patients respond well to 2.4mg but hit a weight loss plateau after 6 to 12 months. Others have a higher body mass that requires more pharmacological support.

Novo Nordisk's STEP UP trial (published late 2025) showed:

• Average weight loss at 7.2mg: 22 to 27% of body weight over 68 weeks
• Compared to 2.4mg: Approximately 5 to 8 percentage points more weight loss
• Plateau breaking: 68% of patients who had plateaued on 2.4mg resumed clinically significant weight loss after escalation to 7.2mg

The dose-response relationship with semaglutide is well-established. Higher doses produce greater appetite suppression and metabolic effects, though side effects also increase.

The Dosing Schedule

Wegovy 7.2mg is not started directly. You must titrate through the standard escalation, then continue upward.

Standard Wegovy Titration (Weeks 1 to 16)

Extended Titration to 7.2mg (Weeks 17 to 32)

Total titration time: Approximately 28 to 32 weeks from first injection to full 7.2mg dose.

Important: Your prescriber may slow the escalation if side effects are problematic. There is no benefit to rushing. The intermediate doses (3.6mg, 5.0mg) are new pen strengths introduced alongside the 7.2mg approval.

What to Expect at Each Stage

Weeks 17 to 20 (2.4mg, Previous Maximum)

Most patients are already familiar with this dose. Appetite suppression is strong. Nausea has usually settled by this point.

Weeks 21 to 24 (3.6mg)

• Appetite suppression intensifies noticeably
• Some patients report a return of mild nausea (similar to initial titration)
• Energy levels may dip temporarily
• Bowel habits may change (constipation or loose stools)

Weeks 25 to 28 (5.0mg)

• Further reduction in hunger cues
• Meal sizes typically decrease again
• Some patients report feeling full after very small portions
• GI side effects tend to stabilise at this stage

Weeks 29 onwards (7.2mg Maintenance)

• Maximum appetite suppression
• Most patients report eating 40 to 60% less than pre-treatment baseline
• Weight loss continues if calorie deficit is maintained
• Side effect profile generally stable (your body has had months to adapt)

Side Effects at 7.2mg

Higher dose means higher incidence of side effects. The STEP UP trial data shows:

Managing Side Effects at Higher Doses

Nausea: Eat smaller, more frequent meals. Avoid fatty or greasy food in the 24 hours after injection. Ginger tea helps. If persistent, your prescriber may slow the titration. The nausea management guide covers ginger, electrolytes and other remedies in detail.

Constipation: Increase fibre intake gradually. Drink at least 2 litres of water daily. Psyllium husk (available from any UK pharmacy) is effective.

Fatigue: Often related to reduced calorie intake rather than the drug itself. Ensure adequate protein (minimum 1.2g per kg body weight). Consider electrolyte supplementation.

Injection site reactions: Rotate sites (abdomen, thigh, upper arm). Allow bruising to resolve before reusing a site.

When to Contact Your Prescriber

• Persistent vomiting (more than 24 hours)
• Severe abdominal pain (could indicate pancreatitis, rare but serious)
• Signs of gallbladder problems (pain under right ribs, especially after eating)
• Inability to keep fluids down
• Symptoms of hypoglycaemia if you take other diabetes medications

Who Qualifies for the 7.2mg Dose

Eligibility Criteria

The 7.2mg dose is not a first-line treatment. You must meet specific criteria:

Required:

• Already on Wegovy 2.4mg for at least 12 weeks
• BMI still 30 or above, OR BMI 27 or above with at least one weight-related comorbidity
• Tolerating 2.4mg without significant adverse effects
• Clinician assessment that higher dose is clinically appropriate

Typical candidates:

• Patients who have plateaued on 2.4mg (weight stable for 8 or more weeks despite adherence)
• Patients with very high starting BMI (40+) who need greater pharmacological support
• Patients who tolerate 2.4mg well but have not reached a healthy weight range

Comorbidities that support qualification:

• Type 2 diabetes or prediabetes
• Hypertension
• Obstructive sleep apnoea
• Cardiovascular disease or high cardiovascular risk
• Non-alcoholic fatty liver disease
• Osteoarthritis related to excess weight

Who Should Not Take 7.2mg

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Severe gastrointestinal disease
• Pregnancy or planning pregnancy
• Under 18 years old

UK Access: NHS and Private

NHS Access

As of April 2026, the 7.2mg dose is not yet routinely available on the NHS. The standard NHS Wegovy programme still prescribes up to 2.4mg.

Expected timeline:

• NICE technology appraisal for 7.2mg: expected Q3 2026
• NHS rollout (if approved): late 2026 to early 2027
• Will likely follow the same eligibility pathway as current NHS Wegovy (BMI criteria, weight management service referral)

Private Access

Several UK private clinics already offer the 7.2mg dose:

Availability:

• Juniper, Numan, and Manual have confirmed 7.2mg availability
• SkinnyJab expected to add it by Q2 2026
• Oviva offering it through their clinical pathway

Cost:

• Expect to pay 15 to 25% more than the 2.4mg dose
• Typical range: £220 to 300 per month at maintenance dose
• Some clinics charge a flat rate regardless of dose; others scale with dose

Process:

1. Must already be an established patient on Wegovy 2.4mg (most clinics require 12 or more weeks)
2. Clinical review with prescriber to assess suitability
3. If approved, new prescription issued with the extended titration schedule
4. Monthly monitoring continues (some clinics increase check-in frequency during escalation)

Switching from Ozempic

If you are currently on Ozempic (maximum 1.0mg for diabetes), switching to Wegovy 7.2mg requires:

• A new clinical assessment for weight management indication
• Starting the Wegovy titration schedule (you may not need to start at 0.25mg if already stable on Ozempic, but your prescriber will advise)
• A different prescription and potentially a different clinic

Cost Comparison

The 7.2mg dose costs more but also delivers more weight loss. Whether the additional cost is justified depends on your response to 2.4mg and your weight loss goals.

Practical Tips for the 7.2mg Transition

1. Do not rush the titration. Each new dose level needs 4 weeks minimum for your body to adjust. Skipping steps increases nausea and dropout risk.

2. Prioritise protein. At higher doses, appetite is significantly suppressed. Without deliberate protein intake, you risk muscle loss. Aim for 1.2 to 1.6g protein per kg of target body weight daily. The complete protein guide for GLP-1 explains food sources, powder strategies and meal plans.

3. Track your weight weekly, not daily. Weight fluctuates. Weekly averages show the real trend.

4. Stay hydrated. Higher semaglutide doses can worsen constipation. Two litres of water per day minimum.

5. Tell your prescriber about all medications. Semaglutide at higher doses may affect absorption of oral medications due to delayed gastric emptying.

6. Plan for reduced appetite. Some patients on 7.2mg genuinely forget to eat. Set meal reminders if needed. Skipping meals leads to muscle loss and nutrient deficiencies.

Key Takeaway

The 7.2mg Wegovy dose is a meaningful advancement for patients who need more weight loss than 2.4mg delivers. It is not for everyone. The titration is slow (28+ weeks to full dose), side effects are higher, and it costs more. But for patients who have plateaued or have very high BMI, the additional 5 to 8 percentage points of weight loss can be clinically significant.

If you are currently on Wegovy 2.4mg and your weight loss has stalled, speak to your prescriber about whether 7.2mg is appropriate for you. Our weight loss plateau guide covers other strategies to try before a dose increase.

Next Steps

• Wegovy vs Ozempic: UK differences explained
• Managing GLP-1 side effects
• What to eat on GLP-1 medication
• UK private GLP-1 clinics compared
• NHS GLP-1 eligibility guide

---

As an Amazon Associate I earn from qualifying purchases.

Disclaimer: This is educational information, not medical advice. The 7.2mg dose requires clinical assessment and prescription. Always consult your prescriber before changing your Wegovy dose.